Ligand-based Molecular Modeling of HDL Receptor SR-BI Inhibitors As Potent Anti-Hyperlipidemic Agents

IF 1.2 4区 医学 Q4 CHEMISTRY, MEDICINAL Letters in Drug Design & Discovery Pub Date : 2024-04-15 DOI:10.2174/0115701808239749230921113101
Swati Verma, Sarvesh Paliwal
{"title":"Ligand-based Molecular Modeling of HDL Receptor SR-BI Inhibitors As Potent Anti-Hyperlipidemic Agents","authors":"Swati Verma, Sarvesh Paliwal","doi":"10.2174/0115701808239749230921113101","DOIUrl":null,"url":null,"abstract":"Introduction:: The High-density lipoprotein (HDL) receptor, Scavenger receptor class B, type I (SRBI) plays a crucial role in lipoprotein metabolism, cholesterol homeostasis, and atherosclerosis. In the present study, a quantitative structure-activity relationship study (QSAR) investigation was conducted on a data set of 31 novel indolinyl thiazole-based inhibitors of SR-BI mediated lipid uptake. Method:: To build the QSAR model, Multiple linear regression analysis (MLR), partial least square analysis (PLS), and neural analysis (NN) were performed which were further evaluated internally as well as externally for the prediction of activity. The best QSAR model for MLR was selected with a correlation coefficient (r2) of 0.937, cross-validation r2cv of 0.908, and a standard error (S) value of 0.253. For PLS, r2 was 0.937 and for FFNN r2 was 0.961 (for the training set). This was further evaluated externally by a test set having r2 values 0.870 (MLR), 0.863(PLS), and 0.933(neural network) analysis. Result:: The final model comprised hydrophobic parameters (Lipole Z component) and steric parameters (molar refractivity and K alpha2 index). Conclusion:: All these descriptors generated comparable results which prove that the model generated is sound and has good predictability.","PeriodicalId":18059,"journal":{"name":"Letters in Drug Design & Discovery","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Letters in Drug Design & Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115701808239749230921113101","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction:: The High-density lipoprotein (HDL) receptor, Scavenger receptor class B, type I (SRBI) plays a crucial role in lipoprotein metabolism, cholesterol homeostasis, and atherosclerosis. In the present study, a quantitative structure-activity relationship study (QSAR) investigation was conducted on a data set of 31 novel indolinyl thiazole-based inhibitors of SR-BI mediated lipid uptake. Method:: To build the QSAR model, Multiple linear regression analysis (MLR), partial least square analysis (PLS), and neural analysis (NN) were performed which were further evaluated internally as well as externally for the prediction of activity. The best QSAR model for MLR was selected with a correlation coefficient (r2) of 0.937, cross-validation r2cv of 0.908, and a standard error (S) value of 0.253. For PLS, r2 was 0.937 and for FFNN r2 was 0.961 (for the training set). This was further evaluated externally by a test set having r2 values 0.870 (MLR), 0.863(PLS), and 0.933(neural network) analysis. Result:: The final model comprised hydrophobic parameters (Lipole Z component) and steric parameters (molar refractivity and K alpha2 index). Conclusion:: All these descriptors generated comparable results which prove that the model generated is sound and has good predictability.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于配体的高密度脂蛋白受体 SR-BI 抑制剂分子模型,作为强效抗高血脂药物
导言高密度脂蛋白(HDL)受体、清道夫受体 B 类 I 型(SRBI)在脂蛋白代谢、胆固醇稳态和动脉粥样硬化中发挥着至关重要的作用。本研究对 31 种新型吲哚啉基噻唑类 SR-BI 介导脂质摄取抑制剂的数据集进行了定量结构-活性关系研究(QSAR)。方法:为建立 QSAR 模型,进行了多元线性回归分析(MLR)、偏最小二乘法分析(PLS)和神经分析(NN),并进一步进行了内部和外部活性预测评估。选出的 MLR 最佳 QSAR 模型的相关系数 (r2) 为 0.937,交叉验证 r2cv 为 0.908,标准误差 (S) 值为 0.253。对于 PLS,r2 为 0.937,对于 FFNN,r2 为 0.961(训练集)。通过测试集进一步进行外部评估,其 r2 值分别为 0.870(MLR)、0.863(PLS)和 0.933(神经网络)。结果::最终模型包括疏水参数(Lipole Z 成分)和立体参数(摩尔折射率和 K alpha2 指数)。结论所有这些描述符都产生了相似的结果,证明所生成的模型是合理的,具有良好的可预测性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.80
自引率
10.00%
发文量
245
审稿时长
3 months
期刊介绍: Aims & Scope Letters in Drug Design & Discovery publishes letters, mini-reviews, highlights and guest edited thematic issues in all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis is on publishing quality papers very rapidly by taking full advantage of latest Internet technology for both submission and review of manuscripts. The online journal is an essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
期刊最新文献
Structural Optimization of Quinazolin-4-One Derivatives as Novel SARS-CoV-2 Mpro Inhibitors by Molecular Simulation Therapeutic Potential of Colchicum luteum Against Flagellin (FliC) in Salmonella typhimurium: An In silico Approach The Therapeutic Potential of Ganoderma lucidum Karst and Ziziphus jujuba Mill for Postsurgical Adhesion Band Formation Indirubin as an AHR Ligand: A Combined Network Pharmacology and Experimental Approach to Psoriasis Therapy Exploring New Potential Pkcθ Inhibitors Using Pharmacophore Modeling, Molecular Docking Analysis, and Molecular Dynamics Simulations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1